{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 461113915
| IUPAC_name = (''RS'')-diethyl (1-<nowiki/>{[(2-chloroethyl)(nitroso)carbamoyl]amino}<br>ethyl)phosphonate
| image = Fotemustine.svg
| width = 200

<!--Clinical data-->
| tradename =  Mustophoran
| Drugs.com = {{drugs.com|international|fotemustine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 92118-27-9
| ATC_prefix = L01
| ATC_suffix = AD05
| ATC_supplemental =  
| PubChem = 104799
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB04106
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 94600
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GQ7JL9P5I2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07255
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 549386

<!--Chemical data-->
| C=9 | H=19 | Cl=1 | N=3 | O=5 | P=1 
| molecular_weight = 315.691 g/mol
| smiles = O=P(OCC)(OCC)C(NC(=O)N(N=O)CCCl)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YAKWPXVTIGTRJH-UHFFFAOYSA-N
}}

'''Fotemustine''' is a [[nitrosourea]] [[alkylating antineoplastic agent|alkylating agent]] approved for use in the treatment of [[metastasis]]ing [[melanoma]].  A study<ref>{{cite journal |vauthors=Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M |date=March 2004 |title=Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study |volume=22 |issue=6 |pmid=15020614 |doi=10.1200/JCO.2004.04.165 |url=http://jco.ascopubs.org/content/22/6/1118.full |pages=1118â€“25}}</ref> has shown that fotemustine produces improved response rates and but does not increase survival (over [[dacarbazine]] in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

==External links==
{{reflist}}

{{Chemotherapeutic agents}}

[[Category:Alkylating antineoplastic agents]]
[[Category:Nitrosamines]]
[[Category:Nitrosoureas]]
[[Category:Organochlorides]]
[[Category:Phosphonate esters]]
[[Category:Ureas]]

{{antineoplastic-drug-stub}}